Fulcrum Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Fulcrum Therapeutics

29/04/2025 14:12

Fulcrum Therapeutics Inc FULC.OQ FULC.O is expected to show no change in quarterly revenue when it reports  results on May 1 for the period ending March 31 2025

​LSEG's mean analyst estimate for Fulcrum Therapeutics Inc is for a loss of 29 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $4.00​, above​ its last closing price of $3.57. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.29
-0.32
-0.31
Beat
3.6
Sep. 30 2024
-0.41
-0.41
-0.35
Beat
13.7
Jun. 30 2024
0.02
-0.01
0.87
Beat
7,060​
Mar. 31 2024
-0.44
-0.44
-0.43
Beat
1.7
​​Dec. 31 2023
-0.42
-0.43
-0.40
Beat
6
Sep. 30 2023
-0.43
-0.43
-0.39
Beat
10.3​
Jun. 30 2023
-0.45
-0.44
-0.38
Beat
14.5
Mar. 31 2023
-0.47
-0.46
-0.41
Beat
10

This summary was machine generated April 29 at 13:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)